J&J: Impella data show lower mortality than CHIP-BCIS3 in high-risk PCI
Johnson & Johnson will present three Impella analyses at TCT 2026, with registry data showing lower mortality than the CHIP-BCIS3 study in high-risk PCI.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, which published a Johnson & Johnson press release, the company will present three clinical analyses of Impella heart pumps at the TCT 2026 symposium. Real-world and observational registry data from 1,379 high-risk PCI patients in the U.S. and Europe showed lower in-hospital cardiovascular mortality and lower 30- and 90-day mortality than the rates recently reported in CHIP-BCIS3.
One analysis of the TRI-GUARD-PCI registry, covering 279 patients in Germany, Switzerland and Austria, reported all-cause mortality of 6.1% at 30 days and 7.9% at 180 days. A separate analysis of PROTECT III found in-hospital all-cause mortality of 4.7% in Impella-supported patients, versus an estimated 8% in CHIP-BCIS3. Results from the randomized PROTECT IV trial are expected in 2027.
why it matters
The news mainly concerns a narrow medtech niche and primarily affects Johnson & Johnson as a device maker. The data are observational and compare results across different studies, so the effect on the company's shares in the broader market is likely to be limited.
tags
instruments
sources
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results — TradingView, 1 November 2026 at 13:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗